EBS News and Press, Emergent Biosolutions Inc. From 04/22/21

Shares of Emergent BioSolutions (NYSE: EBS) were falling 4% as of 11:07 a.m. EDT on Thursday after sinking as much as 7.6% earlier in the day. The stock tumbled earlier this week after the company was forced to halt production at its Bayview facility in Baltimore, Maryland, ...

With the market at or near all-time highs, rising interest rates, and inflation fears looming, it may be time for investors to take a look at the healthcare sector. As compared to the overall market, the healthcare sector's valuation is more reasonable while still exhibiting decent gr...

GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions’ (NYSE:EBS) Baltimore-Bayview facility and provided specific feedback. Given the heightened focus on this facility, the FDA has proa...

On Wednesday, The Food and Drug Administration revealed that Emergent BioSolutions (NYSE: EBS) Baltimore plant, which manufactured Johnson and Johnson Covid-19 vaccines, was unsanitary and unsuitable to produce the shots. The FDA had previously halted the production of the plant a...

The FDA has found nine observations of deficiencies at the Baltimore manufacturing facility of Emergent BioSolutions ([[EBS]] +0.1%).The inspection followed the manufacturing mix-up that made as many as 15M doses of Johnson & Johnson ([[JNJ]] -0.2%) COVID-19 vaccine become usele...

A recently concluded FDA inspection of Emergent BioSolutions (EBS) troubled Baltimore facility has found nine observations of deficiencies.One of them was that the company failed to adequately train employees in manufacturing operations and quality control.Emergent has suspended COVID-19 vacc...

Shares of Emergent Biosolutions Inc. (NYSE:EBS) traded today at $64.87, breaking its 52-week low. This new low was reached on below average trading volume as 490,000 shares traded hands, while the average 30-day volume is approximately 836,000 shares. There is potential upside of 19.3% f...

Launching an investigation into the vaccine contracts secured by Emergent BioSolutions ([[EBS]] -3.8%), the House Oversight Committee and the Select Subcommittee on the coronavirus crisis have asked the CEO and executive chairman of the company asking them to testify at a hearing on May ...

With a ~12.6% drop today, Emergent BioSolutions (EBS) has witnessed its second steepest one-day loss for the year after announcing the ongoing FDA inspections at its Bayview manufacturing facility in Baltimore, Maryland.In late March, 15M doses of Johnson & Johnson's (JNJ) COVID-19 v...

Emergent BioSolutions (NYSE: EBS) has been asked by the Food and Drug Administration to stop production for Covid-19 vaccines. According to the company, the halt comes amid a botched batch of Johnson & Johnson shots within its Baltimore plant. Shares fell 9% following the ne...